The Life Insurance Market
The families of men with advanced prostate cancer will be relieved to hear that a new drug could stave off them claiming on life insurance policies.
Trials have shown that the drugs can extend life by an average of four months in advanced cases, with researchers hopeful that the benefits will be longer-lasting in less severe cases.
The drug interferes with the production of testosterone, which can often fuel the growth of prostate cancer. It also has a lack of side effects, when compared to more traditional treatments, such as chemotherapy and radiotherapy.
Harpal Kumar from Cancer Research UK remarks that "it's certainly a significant improvement in what might be expected for men with such advanced prostate cancer."
The drug's manufacturers Janssen now need a European licence to market the drug, which could bring joy to thousands of families who won't need to claim their life insurance policy quite so soon.
Post your own comment